Merck Q4 2024 Earnings February 4, 2025 -- 1 of 35 -- Agenda 2 Question & Answer Session Financial Results and Outlook Caroline Litchfield Chief Financial Officer Research Update Dr. Dean Li President, Merck Research Laboratories Strategy and Business Update Rob Davis Chairman and Chief Executive Officer -- 2 of 35 -- Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA 3 This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2023 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov). -- 3 of 35 -- Strategy and Business Update Rob Davis Chairman and Chief Executive Officer -- 4 of 35 -- Committed to saving and improving lives around the world 5 Nearly half a billion people reached with our medicines and vaccines in 2024 -- 5 of 35 -- Delivered on our key strategic priorities 6 Advanced the pipeline to meet patient unmet need Executed on strategic business development to augment pipeline Achieved strong commercial and financial performance Created long-term value for patients and shareholders -- 6 of 35 -- 0 10,000 20,000 30,000 40,000 50,000 60,000 70,000 2022 2023 2024 2025 2024 performance1 and 2025 initial guidance 7 1. Results from continuing operations attributable to Merck & Co., Inc. 2. Merck does not exclude expenses for upfront and milestone payments related to certain collaborations and licensing agreements, or charges related to pre-approval assets obtained in transactions accounted for as asset acquisitions from its non-GAAP results. Fourth quarter of 2024 includes a charge of $0.23 per share for such items. Fourth quarter of 2023 includes a charge of $1.69 per share for such items. Full year non-GAAP results for 2024, 2023 and 2022 include $1.28, $6.21, $0.22 per share of such charges, respectively. Full-year 2025 guidance includes ~$0.09 per share of such charges. 3. Full year 2024 GAAP EPS $6.74. 4. Fourth quarter of 2024 GAAP EPS $1.48. $15.6B +7% +9% ex-Exchange Q4 Worldwide Sales $1.72 Q4 Non-GAAP EPS4 $60.1B +1% $5.37 Full Year Sales Full Year Non-GAAP EPS2,3 $59.3B +22% 2022 2023 2024 2025 $1.51 $7.48 $7.65 GUIDANCE RANGE $64.1B - $65.6B +0% - +2% GUIDANCE RANGE $8.88 - $9.03 $64.2B +7% -- 7 of 35 -- Update on GARDASIL in China 8 • Market dynamics remain challenging • Temporarily pausing shipments beginning in February through at least mid-year to accelerate inventory reduction • Expect strong growth in 2H25, 2026 and 2027, irrespective of GARDASIL in China Confidence in ability to successfully navigate the KEYTRUDA LOE period remains unchanged -- 8 of 35 -- Advancing and broadening our diverse pipeline 9 Oncology Cardiometabolic Infectious Disease • FDA acceptance of BLA for clesrovimab to help protect infants from RSV • Topline results for islatravir + doravirine for HIV treatment • Positive topline results for subcutaneous pembrolizumab • Licensed MK-2010, a PD-1/VEGF bispecific antibody, from LaNova • Positive topline results for WINREVAIR from ZENITH trial • Licensed MK-4082, an oral GLP-1 receptor agonist, from Hansoh -- 9 of 35 -- Evolving to a more diversified commercial portfolio with robust Phase 3 development program 10 enlicitide decanoate Oral PCSK9i bomedemstat LSD1i ifinatamab deruxtecan1 B7H3 ADC pembrolizumab + berahyaluronidase alfa SC administration raludotatug deruxtecan1 CDH6 ADC sacituzumab tirumotecan3 TROP2 ADC tulisokibart TL1A MK-3000 Tetravalent tri-specific antibody clesrovimab RSV mAb islatravir + doravirine NRTTI patritumab deruxtecan1 HER3 ADC zilovertamab vedotin ROR1 ADC pembrolizumab + quavonlimab CTLA-4 nemtabrutinib BTKi 2026-2027 2024-2025 opevesostat CYP11A1i MK-10844 KRAS G12Ci V9405 INT 2028+ 20 new growth drivers, almost all of which have blockbuster potential Oncology Infectious Disease / Vaccines Cardiometabolic Ophthalmology / Immunology Note: Timing reflects primary completion date on clinicaltrials.gov. Excludes ongoing Phase 3 studies for marketed products including KEYTRUDA, Lenvima, Lynparza, Verquvo, LAGEVRIO and WELIREG. 1. Collaboration with Daiichi Sankyo 2. Collaboration with Gilead 3. Collaboration with Kelun Biotech 4. Collaboration with Taiho and Astex 5. Collaboration with Moderna islatravir + lenacapavir2 NRTTI -- 10 of 35 -- Updated Opportunity1 >$25B Expanding diverse pipeline to drive patient impact and value creation 11 Oncology Cardiometabolic Immunology HIV Ophthalmology ~$15B >$5B >$5B Multibillion + Infectious Disease / Vaccines • Including clesrovimab, V181 and others Animal Health • Expect revenue to more than double by the mid-2030s Early-Phase Programs • Many advancing to Phase 2 in 2025/2026 Business Development • Significant capacity to further augment pipeline 1. All dollar figures above are non-risk adjusted annual sales by the mid 2030s -- 11 of 35 -- Business/Financial Results and Outlook Caroline Litchfield Chief Financial Officer -- 12 of 35 -- Strong Q4 and 2024 worldwide sales growth 13 Q4 2024 WORLDWIDE SALES1 $15.6B+7% growth +9% ex-Exchange 2 $14.0B +7% growth +8% ex-Exchange 2 Human Health $1.4B +9% growth +13% ex-Exchange 2 Animal Health 1. Worldwide Sales includes Other Revenue. 2. ~1 percentage point of the negative impact of foreign exchange for Human Health sales, ~2 percentage points of the negative impact of foreign exchange for Worldwide sales, and ~3 percentage points of the negative impact of foreign exchange for Animal Health, were due to devaluation of the Argentine peso, which were largely offset by inflation-related price increases, consistent with practice in that market. FULL YEAR WORLDWIDE SALES1 $64.2B+7% growth +10% ex-Exchange 2 Merck -- 13 of 35 -- Oncology: KEYTRUDA continues to grow globally 14 Growth rates exclude the impact of foreign exchange. 1. ~2 percentage point negative impact of foreign exchange were due to devaluation of Argentine peso, which were largely offset by inflation-related price increases, consistent with practice in that market. • KEYTRUDA sales of $7.8B increased 21%1 , driven by continued robust global demand from metastatic indications and uptake from earlier stage cancers – In the U.S., growth reflects increased uptake from KN-A39 in locally advanced or metastatic urothelial cancer and KN-868 in primary advanced or recurrent endometrial cancer, as well as earlier stage NSCLC and TNBC – Outside the U.S., growth reflects continued uptake in earlier stage cancers, including high- risk, early-stage TNBC, as well as demand from metastatic indications $4.2B +20% $3.4B +31% $5.3B +30% 4Q22 4Q23 4Q24 $5.5B +26% $7.8B +21% $6.6B +22% -- 14 of 35 -- Oncology: Strength across broad portfolio 15 • WELIREG sales more than doubled, driven by increased uptake in certain adult patients with previously treated advanced RCC in the U.S. • Lynparza 1 sales grew 18%, primarily due to higher global demand • Lenvima 2 sales grew 14%, primarily due to timing of shipments in certain international markets $181M +15% $151M +57% Growth rates exclude the impact of foreign exchange. 1. In collaboration with AstraZeneca 2. In collaboration with Eisai 4Q22 4Q23 4Q24 $315M +8% $292M +14% $365M +18% 4Q22 4Q23 4Q24 $226M +5% $216M +9% $255M +14% 4Q22 4Q23 4Q24 $72M +78%$40M +245% $160M +123% -- 15 of 35 -- 4Q22 4Q23 4Q24 $1.7B +40% 4Q22 4Q23 4Q24 $1.9B +27% Vaccines: Broad vaccines portfolio driving global impact 16 • GARDASIL sales of $1.6B decreased 18%, driven by lower demand in China – In the U.S., sales benefitted from price and demand, partially offset by CDC purchasing patterns – Outside the U.S. and China, double digit sales growth driven by higher overall demand including catch-up cohort in Japan • VAXNEUVANCE sales of $161M declined 9%, as growth from ongoing launches in international markets more than offset by competitive pressures in the U.S. • CAPVAXIVE sales of $50M, driven by demand from retail pharmacy channel Growth rates exclude the impact of foreign exchange. $1.6B -18% $1.5B +6% $138M $176M +26% $161M -9% -- 16 of 35 -- Cardiovascular: Successful ongoing launch of WINREVAIR 17 Global Q4 sales of $200M Patients • Achieved coverage for >60% of lives since launch • Many payors established coverage policies consistent with the label or STELLAR criteria • ~1,500 new patients prescribed in the quarter • ~5,200 total patients prescribed since launch • ~80% of prescribed patients receive commercial product • ~3,900 commercial patients started treatment since launch • >22,000 total prescriptions filled since launch • >900 physicians have written at least one prescription since launch • Most prescribers are from large academic centers or larger private practices • Increasing percentage of prescriptions are for patients not on prostacyclin background therapy Ex-U.S. U.S. • Launch is on track in Germany • Anticipate securing reimbursement in other European countries in 2H25 Prescribers Payors -- 17 of 35 -- Animal Health: Strong growth across livestock and companion animal 18 • Animal Health sales increased 13% 1 to $1.4B – Livestock sales grew 14%, driven by higher demand for poultry products, inclusion of sales from the recently expanded aqua portfolio, and price – Companion Animal sales growth of 10% reflects price 4Q22 4Q23 4Q24 $1.2B +6% $1.3B +4% $1.4B +13% Growth rates exclude the impact of foreign exchange. 1. ~3 percentage point negative impact of foreign exchange were due to devaluation of Argentine peso, which were largely offset by inflation-related price increases, consistent with practice in that market. -- 18 of 35 -- Q4 2024 non-GAAP financial results summary1 19 Q4 2024 Q4 2023 Change Change Ex-FX Sales $15.6 $14.6 +7% +9% Non-GAAP Gross Margin 80.8% 77.2% +3.6pts +3.3pts Non-GAAP Operating Expenses $7.4 $11.6 -36% -36% Non-GAAP Tax Rate 16.2% 114.2% N/M N/A Non-GAAP EPS2,3 $1.72 $0.03 >100% >100% $ in billions, except EPS amounts 1. Merck is providing certain 2024 and 2023 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results because management uses non-GAAP results to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a attached to the earnings release. 2. Q4 2024 includes a charge of $0.23 per share for the LaNova and Hansoh transactions. Q4 2023 includes a charge of $1.69 per share for the collaboration with Daiichi Sankyo. 3. Q4 2024 GAAP EPS of $1.48 -- 19 of 35 -- Initial 2025 financial outlook 1. Guidance does not assume any additional significant potential business development transactions. 20 Guidance Key Assumptions Revenue $64.1B to $65.6B • Assumes ~2 percentage point FX headwind • Implies +0% to +2% nominal (+2% to +4% ex-FX) • Assumes no further shipments of GARDASIL to China at the low-end and less than $1B at the high-end Non-GAAP Gross Margin Rate ~82.5% Non-GAAP Operating Expenses1 $25.4B to $26.4B • Includes $300M anticipated milestone payment to LaNova associated with technology transfer for MK-2010 Other (Income) / Expense ~$300M to ~$400M of expense Tax Rate ~16.0% to 17.0% Shares Outstanding ~2.53B Non-GAAP EPS1 $8.88 to $9.03 • Includes ~$0.09 charge related to anticipated milestone payment to LaNova associated with technology transfer for MK-2010 • Assumes a negative impact from FX of ~$0.35 -- 20 of 35 -- Key modeling considerations 21 GARDASIL • Withdrawing $11B target given uncertain timing of economic recovery in China • Growth expectations outside of China remain unchanged • Well-positioned to drive strong growth beyond 2025 KEYTRUDA • In the U.S., benefitted from ~$200M of wholesaler buy-in during 4Q24, which is expected to reverse in 1Q25 Medicare Part D Redesign • Anticipate ~$400M negative impact related to Medicare Part D redesign, primarily affecting WINREVAIR, WELIREG, Lynparza and Lenvima JANUVIA Family1 • Lowered list price in the beginning of 2025 to more closely align with net price • Reduced list price will lower rebate amount paid to Medicaid • Expect higher net sales in the U.S. in 2025 • Expect to benefit from continued strength in Oncology and Animal Health, as well as contributions from new product launches • Expect roughly flat YoY revenues in 1H25 and strong YoY growth in 2H25 Sales 1. JANUVIA Family includes JANUVIA, JANUMET and JANUMET XR -- 21 of 35 -- 22 Continue to invest in the pipeline and business while augmenting the pipeline with value-enhancing business development $3.2 $0.9 $2.0 $0.2 $0.5 After-Tax R&D CapEx Dividends Paid Business Development (ex-divestitures) Share Repurchase Q4 Spend ($ in billions) 1 1. Reflects quarter spend 2. Reflects R&D excluding Business Development Remain committed to balanced capital allocation strategy Capital allocation order of priority 2 -- 22 of 35 -- Research Update Dr. Dean Li President, Merck Research Laboratories -- 23 of 35 -- Important updates from across our cardiometabolic pipeline 24 Foundational study supported initial regulatory approval for WINREVAIR as first-in-class treatment for PAH ‒ Submitted for approval in Japan Open-label long-term extension study for patients rolling over from other studies WINREVAIR MK-4082 • Entered exclusive global license agreement with Hansoh to develop preclinical oral small molecule GLP-1 receptor agonist • Well-positioned to advance combinations with next-generation agents for weight loss and cardiometabolic disease Positive topline results in Phase 3 study in adults with PAH FC III or IV at high risk of mortality ‒ Stopped early due to overwhelming efficacy in primary endpoint Phase 3 study in newly diagnosed adults with PAH FC II or III at immediate or high risk of disease progression ‒ Stopped early and moving to final analysis based on totality of clinical benefit -- 24 of 35 -- Building on our strong legacy in infectious disease and vaccines 25 RSV • FDA set PDUFA date of June 10th for clesrovimab, investigational long-acting monoclonal antibody to help protect infants from RSV disease during their first RSV season • If approved, clesrovimab would be the first and only single dose passive immunization for infants regardless of weight Vaccines HIV • Announced topline results from two Phase 3 trials evaluating doravirine and islatravir as once-daily, oral combination treatment option for adults living with HIV infection that is virologically suppressed on different antiretroviral therapy regimens • Advancing MK-8527, once- monthly oral option for PrEP, to Phase 3 this year • GARDASIL approved in China for males 9 to 26 years old to help prevent certain HPV-related cancers and diseases • Presented new clinical and real- world data for GARDASIL 9 at International Papillomavirus Conference • CHMP in Europe recommended approval of CAPVAXIVE for prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults -- 25 of 35 -- Regulatory Developments Strengthening our leadership in oncology U.S. • Sac-TMT2: FDA granted Breakthrough Therapy Designation for treatment of patients with advanced or metastatic nonsquamous NSCLC with EGFR mutations whose disease progressed on or after TKI and platinum-based chemotherapy China • KN-671: NMPA approved KEYTRUDA regimen1 for neoadjuvant and adjuvant treatment for certain patients with resectable NSCLC • KN-A18: NMPA approved KEYTRUDA in combination with chemoradiotherapy for treatment of certain patients with FIGO 2014 Stage III-IVA locally advanced cervical cancer • KN-A39: NMPA approved KEYTRUDA in combination with Padcev for 1L treatment of adult patients with locally advanced or metastatic urothelial carcinoma • LS-004: NMPA approved WELIREG for treatment of adult patients with certain types of VHL disease-associated tumors Japan • KN-A18: MHLW approved KEYTRUDA in combination with chemoradiotherapy for treatment of certain patients with FIGO 2014 Stage III-IVA locally advanced cervical cancer • KN-868: MHLW approved KEYTRUDA in combination with carboplatin and paclitaxel for 1L treatment of certain patients with primary advanced or recurrent endometrial carcinoma • Fixed dose pembrolizumab + berahyaluronidase alfa in combination with chemotherapy met primary pharmacokinetic endpoints in Phase 3 MK-3475A-D77 trial PD-1/VEGF bispecific antibody • Exclusive global license with LaNova to develop MK-2010 Subcutaneous pembrolizumab • More than 20 abstracts presented at ASH 3, including results from Phase 2 waveLINE-007 study evaluating zilovertamab vedotin, an investigational ADC targeting ROR1, in previously untreated patients with diffuse large B-cell lymphoma Hematology 1. KEYTRUDA in combination with platinum-containing chemotherapy as neoadjuvant treatment and continued as monotherapy as adjuvant treatment after surgery 2. Collaboration with Kelun Biotech 3. American Society of Hematology Annual Meeting 26 -- 26 of 35 -- Significant progress across our broad pipeline in 2024 27 >25 >20 Regulatory approvals in major regions, including WINREVAIR and CAPVAXIVE Phase 3 studies initiated across multiple therapeutic areas “One Pipeline ” Complementing internal innovation and discovery efforts with the best external science through business development to advance breakthrough science for patients -- 27 of 35 -- Select milestones in 2025 28 Medical Meeting Presentations Upcoming Data Readouts Cardiometabolic • WINREVAIR - Phase 3 ZENITH study in PAH at American College of Cardiology 2025 Infectious Disease • Islatravir + doravirine - Phase 3 MK-8591A-051 and MK-8591A-052 studies for HIV treatment Oncology • Subcutaneous pembrolizumab plus berahyaluronidase- alfa - Phase 3 MK-3475A-D77 study • KEYTRUDA - Phase 3 KN-689 study in locally advanced HNSCC • Enlicitide decanoate – Phase 3 studies in hypercholesterolemia ‒ CORALreef HeFH (PCD in April) ‒ CORALreef AddOn (PCD in July) ‒ CORALreef Lipids (PCD in August) • WINREVAIR – Phase 2 study in PH due to LHD (PCD in October) -- 28 of 35 -- Q&A Rob Davis Chairman and Chief Executive Officer Dr. Dean Li President, Merck Research Laboratories Caroline Litchfield Chief Financial Officer Peter Dannenbaum Senior Vice President, Investor Relations -- 29 of 35 -- 30 Appendix -- 30 of 35 -- Q4 2024 GAAP financial results summary 31 Q4 2024 Q4 2023 Change Change Ex-FX Sales $15.6 $14.6 +7% +9% Operating Expenses1 $7.4 $12.4 -40% -40% Tax Rate 10.2% 40.1% N/M N/A GAAP Earnings / (Loss) per Share1 $1.48 ($0.48) >100% >100% $ in billions, EPS/LPS amounts 1. 4Q24 GAAP results include a charge of $0.23 per share related to the execution of licensing agreements with LaNova and Hansoh. 4Q23 GAAP results include a charge of $1.69 per share related to the collaboration with Daiichi Sankyo. -- 31 of 35 -- 2024 GAAP financial results summary 32 2024 2023 Change Change Ex-FX Sales $64.2 $60.1 +7% +10% Operating Expenses $28.8 $41.0 -30% -29% Tax Rate 14.1% 80.0% N/M N/A GAAP Earnings per Share $6.74 $0.14 >100% >100% $ in billions, EPS amounts -- 32 of 35 -- 33 E Capital allocation: Trailing twelve months $12.1 $3.4 $7.8 $4.7 $1.3 $0 $3 $6 $9 $12 $15 After-Tax R&D CapEx Dividends Paid Business Development (ex-divestitures) Share Repurchase ~$ 20B Over 5 years, including expanding manufacturing capacity for Oncology, Vaccines, and Animal Health. Includes >$11B in the U.S. Billions Over the past 12 months Capital investments 2024 to 2028 Commitment to the dividend Well-positioned balance sheet with capacity to fund additional value-enhancing business development opportunities Order of priority 1. Reflects R&D excluding Business Development 2. Includes BD payments reflected in operating cash flow 2 1 E $1.80 $1.84 $1.88 $1.92 $2.20 $2.44 $2.60 $2.76 $2.92 $3.08 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Dollars per share +2% +2% +2% +2% +11% +15% +7% +6% +6% +5% -- 33 of 35 -- Driving value for patients and shareholders by progressing our pipeline • In the U.S., the FDA: o Accepted for priority review the sNDA for WELIREG for the treatment of adult and pediatric (12 years and older) patients with advanced, unresectable, or metastatic PPGL o Accepted the BLA for clesrovimab, an investigational prophylactic long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season o Granted Breakthrough Therapy Designation to sac-TMT for the treatment of patients with advanced or metastatic nonsquamous NSCLC with EGFR mutations whose disease progressed on or after TKI and platinum- based chemotherapy • In the EU, the CHMP adopted a positive opinion for: o CAPVAXIVE for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older based on the Phase 3 STRIDE studies o WELIREG for the treatment of adult patients with VHL disease who require therapy for associated, localized RCC, CNS hemangioblastomas, or pNET, and for whom localized procedures are unsuitable based on LITESPARK-004 o WELIREG for the treatment of adult patients with advanced clear cell RCC that progressed following two or more lines of therapy that included a PD-1 or PD-L1 inhibitor and at least two VEGF targeted therapies based on LITESPARK-005 o KEYTRUDA in combination with pemetrexed and platinum chemotherapy, for the first-line treatment of adult patients with unresectable non-epithelioid malignant pleural mesothelioma based on IND.227/KN-483 • In China, the NMPA approved: o GARDASIL for use in males 9-26 years of age to help prevent certain HPV-related cancers and diseases o KEYTRUDA in combination with platinum-containing chemotherapy as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment after surgery for patients with resectable stage II, IIIA, or IIIB NSCLC based on KN-671 o WELIREG for the treatment of adult patients with VHL disease who require therapy for associated RCC, CNS hemangioblastomas or pNET, not requiring immediate surgery based on LITESPARK-004 o KEYTRUDA in combination with enfortumab vedotin for the treatment of adult patients with locally advanced or metastatic urothelial cancer based on KN-A39 o KEYTRUDA for the treatment of certain types of locally advanced cervical cancer based on KN-A18 • In Japan, the MHLW approved: o KEYTRUDA for the treatment of advanced and recurrent endometrial cancer in combination with chemotherapy based on KN-868/NRG-GY018 o KEYTRUDA in combination with CCRT for the treatment of locally advanced cervical cancer based on KN-A18 Announced: • Phase 3 switch trials evaluating doravirine/islatravir met primary efficacy hypotheses in adults with HIV-1 infection that is virologically suppressed on different antiretroviral therapy regimens • Phase 3 ZENITH trial evaluating WINREVAIR was stopped early after meeting its primary endpoint of time to first morbidity or mortality event for the treatment of patients with PAH FC III or IV at high risk of mortality at interim analysis • Phase 3 HYPERION trial evaluating WINREVAIR in recently diagnosed adults with PAH FC II or III at intermediate or high risk of disease progression will be stopped early due to the positive results from the interim analysis of the ZENITH trial and a review of the totality of data from the WINREVAIR clinical program to date • Phase 3 MK-3475A-D77 trial met its dual primary PK endpoints as subcutaneous administration of pembrolizumab together with berahyaluronidase alfa administered with chemotherapy for the first-line treatment of adult patients with metastatic NSCLC Presented data for: • Phase 3 OlympiA trial evaluating Lynparza at the 2024 San Antonio Breast Cancer Symposium showing long-term data on OS, IDFS and DDFS for people with gBRCAm HER2-negative high-risk early breast cancer • Approved and investigational medicines across multiple hematologic malignancies at the American Society of Hematology (ASH) Annual Meeting and Exposition including for zilovertamab vedotin (ROR1 ADC), nemtabrutinib (BTKi), bomedemstat (LSD1i), and KEYTRUDA • GARDASIL 9 at the International Papillomavirus Conference (IPVC) 2024 including new clinical and real-world data evaluating the burden and incidence of certain HPV-related cancers and diseases Key regulatory milestones since the last earnings call: 34 Key data & clinical advancements since the last earnings call: -- 34 of 35 -- Broad and innovative pipeline to address significant unmet medical needs Phase 2 Phase 3 Under regulatory review KEYTRUDA (MK-3475) Advanced Solid Tumors Prostate MK-3475A (pembrolizumab + berahyaluronidase alfa) cSCC Hematological Malignancies MK-5890 (boserolimab)2 Neoplasm Malignant MK-5909 (raludotatug deruxtecan)1 Bladder Cervical Endometrial Ovarian RCC WELIREG (MK-6482)3 Breast Endometrial Esophageal HCC LYNPARZA (MK-7339)1,3 Advanced Solid Tumors V940 1,2 Bladder RCC MK-1022 (patritumab deruxtecan)1 Biliary Bladder Cervical CRC Endometrial Esophageal Gastric HCC HNSCC Melanoma Ovarian Pancreas Prostate MK-1308 (quavonlimab)2 NSCLC MK-1308A (quavonlimab +pembrolizumab) CRC MK-2400 (ifinatamab deruxtecan)1 Biliary Bladder Breast Cervical CRC Endometrial Esophageal HCC HNSCC Melanoma Ovarian Pancreas MK-2870 (sacituzumab tirumotecan)1,3 Biliary CRC Neoplasm Malignant Pancreatic Oncology Oncology MK-1022 (patritumab deruxtecan)1 NSCLC (EU) MK-1026 (nemtabrutinib) Hematological Malignancies MK-10842 NSCLC MK-1308A (quavonlimab +pembrolizumab) RCC MK-2140 (zilovertamab vedotin) Hematological Malignancies MK-2400 (ifinatamab deruxtecan)1 SCLC MK-2870 (sacituzumab tirumotecan)1,3 Breast Cervical Endometrial Gastric NSCLC MK-3543 (bomedemstat) Myeloproliferative Disorders KEYTRUDA (MK-3475) Hepatocellular (EU) Ovarian SCLC MK-3475A (pembrolizumab + berahyaluronidase alfa) NSCLC MK-5684 (opevesostat) Prostate LYNPARZA (MK-7339)1,2 NSCLC SCLC LENVIMA (MK-7902)1,2 Esophageal V940 1,2 Melanoma NSCLC Infectious Disease MK-8591A (doravirine+islatravir)5 HIV-1 Infection MK-8591D (islatravir+lenacapavir)1,5 HIV-1 Infection LAGEVRIO (MK-4482)1,6 COVID-19 Antiviral MK-7240 (tulisokibart) Crohn’s Disease Ulcerative Colitis Immunology Cardiometabolic MK-0616 (enlicitide decanoate) Hypercholesterolemia As of February 25, 2025 Oncology KEYTRUDA (MK-3475) Mesothelioma (EU, JPN) MK-1022 (patritumab deruxtecan)1,8 NSCLC (US) WELIREG (MK-6482) Advanced RCC (JPN) Certain VHL Tumors (JPN) PPGL (US) Vaccines CAPVAXIVE (V116) Pneumococcal Vaccine Adult (EU, JPN) MK-3000 7 Diabetic Macular Edema Ophthalmology V181 Dengue Fever Virus Vaccines Infectious Disease MK-8527 HIV-1 PrEP MK-8591B (islatravir+MK-8507)4 HIV-1 Infection MK-5475 PH-COPD MK-6024 (efinopegdutide) MASH WINREVAIR (MK-7962) Pulmonary Hypertension due to Left Heart Disease Cardiometabolic MK-6194 Lupus Vitiligo MK-7240 (tulisokibart) Systemic Sclerosis Immunology MK-1167 Alzheimer’s Neuroscience Infectious Disease MK-1654 (clesrovimab) Respiratory Syncytial Virus (US, EU) Cardiometabolic WINREVAIR (MK-7962) Pulmonary Arterial Hypertension (JPN) 35 1. Being developed in a collaboration 2. Being developed in combination with KEYTRUDA 3. Being developed as monotherapy and/or in combination with KEYTRUDA 4. FDA lifted clinical hold on 12/4/2024 5. On partial clinical hold for higher doses of islatravir than those used in current clinical trials 6. Available in the U.S. under Emergency Use Authorization 7. Program is in Phase 2/3 study 8. In June 2024, FDA issued a CRL for the BLA for patritumab deruxtecan. Merck is working with Daiichi Sankyo to address FDA feedback -- 35 of 35 --